Hereditary Angioedema Treatments Market Worth USD 6,533.3 Million at 16.8% CAGR Forecast by 2025

In its report titled, ‘Hereditary Angioedema Treatment Market: Global Market Analysis, Insights and Forecast, 2018-2025,’ Fortune Business Insights studies the current market scenario, including contribution of leading companies such as CSL Behring, Shire Inc., and Pharming Group NV towards the market’s growth trajectory.

Furthermore, the report finds that the Global Hereditary Angioedema Treatment Market will rise from its 2017 value of US$ 1,883.1 Mn to an estimated valuation of US$ 6,533.3 by the end of 2025, thereby exhibiting a CAGR of 16.8%.

In August 2018, the European Medicines Agency CHMP recommended ‘Takhzyro’, a drug introduced by Shire, for the treatment of hereditary angioedema. Shire launched Takhzyro with a view to tackle Haegarda, a drug marketed by CSL Behring, that has already established itself in the market.

In 2017, with a view to block CSL’s Haegarda, Shire put in numerous legal efforts, with claims that it breached the terms of its own patent. As observed, both companies are bringing in new drugs and treatments in order to stay ahead of competition. The global angioedema treatment market is expected to benefit significantly from similar launches of novel therapeutics.

Successive clinical approvals of angioedema related drugs in recent years are favoring growth of the global hereditary angioedema treatment market. With a portfolio of patented drugs, CSL, Shire, and Pharming Group NV together accounted for more than half of the global hereditary angioedema treatments market.

Because a handful of companies enjoy a lion’s share, the global hereditary angioedema treatments market is consolidated in nature. Some of the other companies operating in the market are Biocryst Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Attune Pharmaceuticals, Arrowhead Pharmaceuticals, Inc., and Adverum.

High Health Risks and Subsequent Emphasis On Hereditary Angioedema May Boost the Global Market

Hereditary angioedema can be potentially life threatening due to the adverse effects it has on those affected. Hereditary angioedema can affect from 1 in 10,000 people to 1 in 50,000 people. Familial history is the main cause of angioedema disorder and almost 50% of all angioedema cases are trace their origin to hereditary conditions.

Although presence of no familial history may lead to lower risks, but it does not completely rule out the risk because there is a huge possibility that it may also result from genetic mutation. Numerous treatment options for hereditary angioedema and growing adoption of angioedema due to diagnostic advances are favoring expansion of the global market. Furthermore, increasing cases of genetic mutations that lead to the disorder are likely to boost global hereditary angioedema treatment market over the forecast period.

C-1 Esterase Inhibitors Likely to Be the Most Widely Used Drug Class

According to the U.S. Hereditary Angioedema Association, hereditary angioedema can occur in individuals with no prior familial history of the disease. It also states that almost 25% of the angioedema cases may arise due to the mutation of a gene called C1-Esterase Inhibitor. The C-1 esterase inhibitors segment accounted for 61.3% of the global hereditary angioedema treatment market in 2017.

North America to Account for the Highest Market Share

The hereditary angioedema treatment market in North America was valued at US$ 1,752.2 Mn in 2017 and is likely to remain dominant in the global market through the forecast period. The increasing prevalence of hereditary angioedema and numerous treatment options for hereditary angioedema in North America are likely to boost the regional market. Presence of a well-established healthcare infrastructure and favorable reimbursement policies are favoring growth of the hereditary angioedema treatments market in North America.

Browse Complete Report Details: https://www.fortunebusinessinsights.com/industry-reports/hereditary-angioedema-treatment-market-100164

The Global Hereditary Angioedema Treatments Market is segment based on: